Hims & Hers Health (HIMS) AI Stock Analysis

• Market Cap: $8.10B
• Dividend Yield: N/A
• Average Volume (3M): 17.75M
• Price to Earnings (P/E): 65.7
• Beta (1Y): 2.68
• Revenue Growth: 78.02%
• EPS Growth: 28.15%
• Country: US
• Employees: 1,637
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): 0.06
• Shares Outstanding: 219,270,890
• 10 Day Avg. Volume: 12,637,085
• 30 Day Avg. Volume: 17,747,723
• PEG Ratio: -0.07
• Price to Book (P/B): 10.95
• Price to Sales (P/S): 3.54
• P/FCF Ratio: 26.33
• Enterprise Value/Market Cap: 1.80
• Enterprise Value/Revenue: 6.60
• Enterprise Value/Gross Profit: 8.80
• Enterprise Value/Ebitda: 92.41
• 1Y Price Target: $44.71
• Price Target Upside: 28.59% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 11
• EPS Forecast (FY): 0.47
• Revenue Forecast (FY): $2.35B

• Rating: 68 Neutral
• Price Target: $43.00 ▲(23.67% Upside)

Hims & Hers Health's strong financial performance and positive earnings call guidance are offset by technical indicators suggesting bearish momentum and a high P/E ratio indicating overvaluation. The new share buyback program adds a positive strategic element, but high leverage remains a concern.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market reach and product adoption, supporting long-term business sustainability.

International Expansion

Expansion into Canada enhances market presence and diversifies revenue streams, contributing to long-term growth potential.

Innovative Product Launches

New product offerings in key health areas can drive future growth and strengthen competitive positioning in the telehealth market.

Negative Factors

High Leverage

Significant leverage can strain financial flexibility and increase risk, potentially impacting long-term financial stability.

Gross Margin Decline

Declining gross margins could pressure profitability, affecting the company's ability to sustain long-term operational efficiency.

Increased G&A Costs

Rising G&A expenses may limit profitability and cash flow, challenging the company's ability to maintain cost efficiency.

Hims & Hers Health Business Overview & Revenue Model

Company Description

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

How the Company Makes Money

Hims & Hers Health generates revenue through multiple streams, primarily by selling prescription medications and health-related products directly to consumers. The company operates on a subscription-based model for certain products, which provides recurring revenue. Additionally, HIMS earns income from telehealth consultations, where customers pay for access to healthcare providers. Strategic partnerships with pharmacies and healthcare networks also contribute to its revenue, enabling HIMS to efficiently distribute its products. The company's focus on branding and marketing enhances customer acquisition, further driving sales and profitability.

Hims & Hers Health Financial Statement Overview

Summary

Hims & Hers Health shows strong revenue and profit growth with a healthy gross profit margin and improved net profit margin. However, the high debt-to-equity ratio indicates significant leverage, posing a potential risk.

Income Statement

Hims & Hers Health has demonstrated strong revenue growth with a TTM revenue increase of 9.81%. The company has maintained a healthy gross profit margin of 76.20% and improved its net profit margin to 9.62% in the TTM period. EBIT and EBITDA margins have also shown positive trends, indicating improved operational efficiency. However, the gross profit margin has slightly decreased compared to the previous year.

Balance Sheet

The company has a high debt-to-equity ratio of 1.86 in the TTM period, indicating significant leverage. However, the return on equity has improved to 38.17%, showcasing effective use of equity to generate profits. The equity ratio stands at 26.00%, reflecting a moderate level of financial stability.

Cash Flow

Hims & Hers Health has shown a positive free cash flow growth rate of 10.07% in the TTM period, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.96, suggesting efficient conversion of income into cash. However, the free cash flow to net income ratio of 0.46 indicates room for improvement in cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.21B	1.48B	872.00M	526.92M	271.88M	148.76M
Gross Profit	1.66B	1.17B	714.95M	408.72M	204.49M	109.45M
EBITDA	157.91M	78.99M	-19.94M	-61.22M	-110.97M	-14.09M
Net Income	133.79M	126.04M	-23.55M	-65.68M	-107.66M	-18.11M
Balance Sheet
Total Assets	2.23B	707.54M	441.19M	366.34M	420.58M	118.70M
Cash, Cash Equivalents and Short-Term Investments	629.74M	300.25M	220.98M	179.63M	247.27M	100.21M
Total Debt	1.12B	11.35M	9.95M	5.31M	5.48M	0.00
Total Liabilities	1.65B	230.82M	97.16M	54.60M	85.97M	265.57M
Stockholders Equity	580.98M	476.72M	344.03M	311.74M	334.62M	-146.87M
Cash Flow
Free Cash Flow	131.54M	198.33M	46.99M	-33.78M	-39.42M	-6.71M
Operating Cash Flow	325.08M	251.08M	73.48M	-26.53M	-34.41M	-2.48M
Investing Cash Flow	-958.49M	-19.05M	-12.11M	34.70M	-156.27M	-39.70M
Financing Cash Flow	813.49M	-107.84M	-11.47M	-33.13M	235.04M	47.74M

Hims & Hers Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 34.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Negative. The current price of 34.77 is below the 20-day moving average (MA) of 37.40, below the 50-day MA of 42.14, and below the 200-day MA of 45.77, indicating a bearish trend. The MACD of -1.55 indicates Negative momentum. The RSI at 40.57 is Neutral, neither overbought nor oversold. The STOCH value of 9.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIMS.

Hims & Hers Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DOCS	72 Outperform	$8.23B	34.69	24.61%	―	20.21%	44.14%
HIMS	68 Neutral	$8.10B	65.74	26.21%	―	78.02%	28.15%
GDRX	65 Neutral	$943.62M	31.90	4.90%	―	1.30%	―
NUS	61 Neutral	$509.93M	4.81	14.55%	2.34%	-12.10%	―
EPC	58 Neutral	$843.33M	34.01	1.62%	3.37%	-1.34%	-73.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TDOC	47 Neutral	$1.29B	-5.58	-15.42%	―	-2.37%	77.85%

Hims & Hers Health Corporate Events

Hims & Hers Health Announces New Share Buyback Program

On November 13, 2025, Hims & Hers Health, Inc. announced a new share repurchase program allowing the company to buy back up to $250 million of its Class A common stock, set to expire in 2028. This initiative follows the completion of a prior repurchase program where the company bought back 1,334,572 shares for $55.5 million between October 1 and November 7, 2025, indicating a strategic move to manage its equity and potentially enhance shareholder value.

Hims & Hers Health Announces COO Transition

On September 28, 2025, Hims & Hers Health, Inc. announced that its Chief Operating Officer, Nader Kabbani, will transition to an advisory role effective November 2, 2025, providing strategic guidance until July 2026. Mike Chi, currently the Chief Commercial Officer, will assume the role of Chief Operating Officer, consolidating operations, marketing, product, and commercial functions. Chi, who joined the company in April 2021, brings over 20 years of experience in consumer internet and has previously held senior marketing roles at Zola, INTERMIX, and Gilt Groupe. The company’s Compensation Committee will review Chi’s compensation in light of his new responsibilities.

Hims & Hers Health Expands Information Dissemination Strategy

Hims & Hers Health, Inc. has announced that it will disseminate information about its operations, products, and services through various public channels, including its websites, social media accounts, and press releases. This approach aims to ensure broad and inclusive distribution of material information to the public, potentially impacting how stakeholders access updates about the company’s activities.